• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Motesanib

Motesanib

Product ID M5876
Cas No. 453562-69-1
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $112.60 In stock
5 mg $217.90 In stock
10 mg $413.30 In stock
25 mg $736.20 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Motesanib is an inhibitor of VEGFR 1/2/3, PDGFR, c-Kit, and RET that displays anticancer chemotherapeutic and anti-angiogenic activities. In vivo, motesanib inhibits tumor growth of xenografts of various cancers. Motesanib is currently in clinical trials as a potential treatment for non-small cell lung cancer (NSCLC), breast cancer, and medullary thyroid cancer.

Product Info

Cas No.

453562-69-1

Purity

≥98%

Formula

C22H23N5O

Formula Wt.

373.45

Chemical Name

N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide

IUPAC Name

N-(3,3-dimethyl-1, 2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide

Synonym

AMG-706

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

M5876 MSDS PDF

Info Sheet

M5876 Info Sheet PDF

References

Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012 Oct;84(1):47-58. PMID: 22405734.

Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012 Sep 19;11:70. PMID: 22992329.

Coxon A, Bready J, Kaufman S, et al. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest. 2012 Feb;35(2):181-90. PMID: 21422803.

Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. PMID: 21534718.

Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66(17):8715-21. PMID: 16951187.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • W5769

    Wortmannin

    Steroid produced by Penicillum; PI3K, mTOR, DNA...

    ≥97%
  • G1310

    GDC-0349

    mTOR inhibitor.

    ≥98%
  • P0346

    Palosuran Hydrochloride

    Urotensin II receptor antagonist.
  • A0902

    N-Acetyl-S-(N′-phenylhexylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant; HDAC inhib...

    ≥98%
  • C2943

    Chlorogenic Acid (from Eucommia)

    Polyphenol derivative of caffeic acid found in ...

    ≥98%
  • C281006

    Chaetocin

    Chaetocin is naturally produced by Chaetomium s...

    ≥98%
  • O4532

    Oligomycin B

    Macrolide; F1F0 ATP synthase inhibitor.

    ≥97%, TLC, HPLC
  • T5720

    Tofacitinib Citrate

    JAK1/2/3 inhibitor.

    ≥99%
  • C4535

    Clinafloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • C0140

    Calcitonin, eel

    Endogenous neuropeptide hormone, lowers extrace...

    ≥95%
  • N4974

    NMS-E628

    ALK and Ros1 inhibitor, Trk antagonist.

    ≥98%
  • E7758

    Etomidate

    GABA-A agonist.

    ≥99%
  • S9754

    Syntide 2

    Synthetic peptide, CDPK, PKC, CaMKII substrate....

    ≥95%
  • A1319

    Adenosine Triphosphate Disodium Hydrate

    Endogenous coenzyme, unit of cellular energy, r...

    ≥95%
  • K9858

    Kyotorphin

    Opioid neuropeptide; kyotorphin agonist.

    ≥95%
  • R0247

    Raltegravir

    HIV integrase inhibitor.

    ≥99%
  • A965121

    AZD-5438

    Inhibitor of CDK.

    ≥98%
  • A0965

    Adrenocorticotropic Hormone (1-14)

    Endogenous peptide hormone fragment, involved i...

    ≥95%
  • P337538

    (-)-Pinostrobin

    Neuroprotective flavonoid

    ≥99%
  • A7668

    Atracurium Besylate

    Non-depolarizing NMJ blocker; AChR antagonist.<...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only